MedTrace Logo

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

NCT01511172 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2017-01-25

No results posted yet for this study

Summary

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).

Conditions

Interventions

DRUG

liraglutide

Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously

DRUG

metformin

1000 mg daily, administered orally

DRUG

placebo

Metformin placebo administered orally. 1000 mg daily

DRUG

placebo

NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously

DRUG

glimepiride

Individually adjusted dose, administered orally

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • Australia
  • Austria
  • Czechia
  • Denmark
  • France
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511172 on ClinicalTrials.gov